Key Performance
More- Earnings Score: N/A
- Momentum Score: 83
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
DarioHealth Reports First Quarter 2026 Financial and Operating Results
DarioHealth (NASDAQ: DRIO) reported Q1 2026 results with second consecutive quarter of sequential revenue growth to $5.6 million, though down year-over-year due to non-recurrence of pharmaceutical customer revenue. The company achieved 21% year-over-year operating expense reduction and improved operating loss by 22% YoY. Channel partnerships now provide access to 116+ million covered lives, with potential expansion to 175+ million. The company maintains $20 million in cash and continues focus on subscription-based recurring revenue and AI-driven engagement programs.
05/13/2026, 6:30 AM • Benzinga
DarioHealth to Report First Quarter 2026 Results on Wednesday, May 13, 2026
DarioHealth Corp. (NASDAQ: DRIO), a digital health company specializing in chronic condition management, announced it will release its Q1 2026 financial results on May 13, 2026 at 8:30 a.m. ET. The company will host a conference call and webcast with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda to discuss results.
05/04/2026, 8:30 AM • Benzinga
A study published in JMIR by Sanofi and Symphony Health revealed that DarioHealth's digital diabetes intervention platform can reduce healthcare costs by an estimated $5,077 per user annually, with 23% lower hospitalization rates and 26% lower all-cause medical charges.
11/24/2025, 8:00 AM • Benzinga
DarioHealth Reports Third Quarter 2025 Financial and Operating Results
DarioHealth reported Q3 2025 revenue of $5.0 million, down from $7.4 million in Q3 2024, but highlighted strong business fundamentals including 60% GAAP gross margin and 45 new signed accounts for 2026 revenue.
11/13/2025, 6:30 AM • Benzinga
DarioHealth revealed research at ISPOR Europe 2025 showing its digital health platform can significantly reduce medical costs, particularly among high-risk populations, by using connected devices, AI-driven insights, and human coaching across multiple chronic conditions.
11/12/2025, 8:30 AM • Benzinga
Why Top KingWin Shares Are Trading Higher By 87%; Here Are 20 Stocks Moving Premarket
Top KingWin shares surged 87.4% in pre-market trading after announcing a sales contract for 10,000 AI Robots. Several other stocks showed significant movement, with some gaining and others declining based on company-specific news and financial results.
09/26/2025, 6:25 AM • Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.
09/25/2025, 5:06 PM • Benzinga
DarioHealth announced securing five new employer contracts for its digital health solutions, covering 107,000 lives and representing a significant expansion of its cardiometabolic health services, with the largest contract to date contributing to annual recurring revenues starting Q3 2025.
09/02/2025, 7:30 AM • Benzinga
DarioHealth to Report Second Quarter 2025 Results on Tuesday, August 12, 2025
DarioHealth Corp. will release its Q2 2025 financial results on August 12, 2025, hosting a conference call at 8:30 a.m. Eastern Time with key executives discussing the company's performance.
08/05/2025, 8:30 AM • Benzinga
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
DarioHealth Corp. operates as a digital health company in the United States and internationally. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.